Live Feeds
● LIVE Updated 47m ago Β· 12 sources tracked

Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials

New Phase III clinical trial research published in the New England Journal of Medicine demonstrates that the experimental weight-loss drug retatrutide provides significant pain relief and weight reduction for people with knee osteoarthritis and obesity. In trials involving more than 1,000 participants combined, individuals taking the highest dose of the injectable drug lost roughly one-quarter of their body weight on average. Furthermore, about two-thirds of the participants experienced at least a 50 percent reduction in their knee pain, improving physical function for everyday activities.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (12)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ Experimental weight-loss drug retatrutide led participants to lose up to 25 percent of their body weight in clinical trials.
  • βœ“ About two-thirds of participants experienced at least a 50 percent reduction in knee pain.
  • βœ“ The research involved more than 1,000 participants combined across two Phase III clinical trials.
  • βœ“ Eli Lilly is highlighting data for retatrutide, Taltz, and Zepbound at ACR Convergence 2026.
πŸ›‘οΈ Source Corroboration: 12 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Northwestern-led Phase III clinical trial results published in the New England Journal of Medicine established that retatrutide reduces both body weight and knee osteoarthritis pain.

Live updates

  1. Experimental Drug Retatrutide Eases Knee Osteoarthritis Pain

    New Phase III clinical trial research published in the New England Journal of Medicine demonstrates that the experimental weight-loss drug retatrutide provides significant pain relief and weight reduction for people with knee osteoarthritis and obesity. In trials involving more than 1,000 participants combined, individuals taking the highest dose of the injectable drug lost roughly one-quarter of their body weight on average. And about two-thirds of the participants experienced at least a 50 percent reduction in their knee pain, improving physical function for everyday activities.

    Why it matters

    Osteoarthritis in the knee causes everyday activities like walking, standing, and climbing stairs to be painful and difficult for overweight individuals. Eli Lilly is showcasing new clinical data for retatrutide alongside other treatments at ACR Convergence 2026, highlighting the intersection of rheumatologic conditions and obesity. Northwestern University researchers led the clinical trials evaluating the triple-target incretin drug.

    What is confirmed

    • Experimental weight-loss drug retatrutide led participants to lose up to 25 percent of their body weight in clinical trials.
    • About two-thirds of participants experienced at least a 50 percent reduction in knee pain.
    • The research involved more than 1,000 participants combined across two Phase III clinical trials.
    • Eli Lilly is highlighting data for retatrutide, Taltz, and Zepbound at ACR Convergence 2026.

    Still unconfirmed

    • Eli Lilly stock is currently 8 percent undervalued based on ACR data highlights.

    What to watch next

    • Further regulatory developments and commercialization timelines for retatrutide
    • Additional data presentations at ACR Convergence 2026 regarding rheumatologic conditions and obesity
    Sources used for this update (13)
    1. health.yahoo.com β€” Is It Mom Brain? Or Is It Actually ADHD?
    2. Medical Xpress β€” Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
    3. New Atlas β€” Knee osteoarthritis pain relief – and massive weight loss – from new GLP-1
    4. MedPage Today β€” Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity
    5. Yahoo Finance β€” Eli Lilly (LLY) Highlights ACR Data, Is The Stock Still 8% Undervalued?
    6. Eli Lilly β€” Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
    7. 쑰선일보 β€” Eli Lilly's Retatrutide Reduces Weight, Knee Pain
    8. Medscape β€” Retatrutide Improves Knee OA Pain, Physical Function
    9. Crain's Chicago Business β€” Northwestern researchers find Lilly’s new weight-loss drug may improve bad knees
    10. www.empr.com β€” Novel Intra-Articular Injection Rapidly Improves Pain and Function in Knee OA
    11. news.northwestern.edu β€” Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
    12. news.northwestern.edu β€” Experimental weight-loss drug eases painful knee ...
    confidence 100%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community